Automate Your Wheel Strategy on MDT
With Tiblio's Option Bot, you can configure your own wheel strategy including MDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDT
- Rev/Share 26.6854
- Book/Share 37.557
- PB 2.5727
- Debt/Equity 0.5974
- CurrentRatio 2.0141
- ROIC 0.0619
- MktCap 123316507846.0
- FreeCF/Share 4.1378
- PFCF 23.2541
- PE 26.4349
- Debt/Assets 0.3145
- DivYield 0.0293
- ROE 0.0962
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MDT | Wolfe Research | Underperform | Peer Perform | -- | -- | June 30, 2025 |
| Initiation | MDT | Leerink Partners | -- | Outperform | -- | $110 | June 16, 2025 |
| Upgrade | MDT | Citigroup | Neutral | Buy | $92 | $107 | March 4, 2025 |
| Upgrade | MDT | RBC Capital Mkts | Sector Perform | Outperform | $98 | $105 | Oct. 10, 2024 |
| Reiterated | MDT | Oppenheimer | -- | Perform | $92 | $94 | Aug. 21, 2024 |
News
MDT Stock Trades Cheaper Than Peers Ahead of Q3 Earnings: Time to Buy?
MDT
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.
Read More
About Medtronic plc (MDT)
- IPO Date 1973-05-02
- Website https://www.medtronic.com
- Industry Medical - Devices
- CEO Geoffrey Straub Martha
- Employees 95000
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.